ValiRx (LON:VAL) has received final approval to start its Phase I/II study for its lead compound on advanced prostate and other solid tumour sufferers.
Dr Satu Vainikka, chief executive, said it was a key moment for any drug-discovery company to get to this point.
The trial had been structured not only to test the safety and tolerance of VAL201 but also to assess if it had an impact on the patient’s clinical condition. House broker Daniel Stewart said this additional data will make VAL201 more attractive to potential partners.
The preliminary outcomes from the first cohort are anticipated during the first quarter of next year.
Patients will be volunteers with locally advanced or metastatic prostate cancers primarily, but other advanced tumour types for which no standard effective therapy is currently available will be also be included in the trial.